Publication details

Improving outcomes of childhood and young adult non-Hodgkin lymphoma: 25 years of research and collaboration within the framework of the European Intergroup for Childhood Non-Hodgkin Lymphoma

Authors	BEISHUIZEN Auke MELLGREN Karin ANDRES Mara AUPERIN Anne BACON Chris M BOMKEN Simon BURKE G A Amos BURKHARDT Birgit BRUGIERES Laurence CHIANG Alan K S DAMM-WELK Christine AMORE Emanuele HORIBE Keizo KABICKOVA Edita KHANAM Tasneem KONTNY Udo KLAPPER Wolfram LAMANT Laurence MARIE-CECILE Le Deley LOEFFEN Jan MACINTYRE Elizabeth MANN Georg MEYER-WENTRUP Friederike MICHGEHL Ulf MINARD-COLIN Veronique MUSSOLIN Lara OSCHLIES Ilske PATTE Catherine PILLON Marta REITER Alfred RIGAUD Charlotte RONCERY Leila SALAVERRIA Itziar SIMONITSCH-KLUPP Ingrid UYTTEBROECK Anne VERDU-AMOROS Jaime WILLIAMS Denise WOESSMANN Wilhelm WOTHERSPOON Andrew WROBEL Grazyna ZIMMERMANN Martin ATTARBASCHI Andishe TURNER Suzanne Dawn
Year of publication	2023
Type	Article in Periodical
Magazine / Source	LANCET HAEMATOLOGY
MU Faculty or unit	Central European Institute of Technology
Citation
web	https://www.sciencedirect.com/science/article/pii/S235230262200374X?via%3Dihub
Doi	http://dx.doi.org/10.1016/S2352-3026(22)00374-X
Keywords	LARGE-CELL; LYMPHOMA; MINIMAL RESIDUAL DISEASE; BURKITTS-LYMPHOMA; GENE-EXPRESSION
Description	The European Intergroup for Childhood Non-Hodgkin Lymphoma (EICNHL) was established 25 years ago with the goal to facilitate clinical trials and research collaborations in the field both within Europe and worldwide. Since its inception, much progress has been made whereby major improvements in outcomes have been achieved. In this Review, we describe the different diagnostic entities of non-Hodgkin lymphoma in children and young adults describing key features of each entity and outlining clinical achievements made in the context of the EICNHL framework. Furthermore, we provide an overview of advances in biopathology with an emphasis on the role of biological studies and how they have shaped available treatments. Finally, for each entity, we describe future goals, upcoming clinical trials, and highlight areas of research that require our focus going forward.